Noah Johnson, PhD
Assistant Research Professor, Neurology

Publications

• Johnson NR, Wang ACJ, Coughlan C, Sillau S, Lucero E, Viltz L, Markham N, Allen C, Dhanasekaran AR, Chial HJ, Potter H. Imipramine and olanzapine block apoE4-catalyzed polymerization of Aß and show evidence of improving Alzheimer’s disease cognition. Alz Res Ther. 2022, 14(1):88. PMID: 35768831.
• Johnson NR. Tau acetylation reduces its autophagic degradation and is a targetable pathway for human tauopathies. BioEssays. 2022, 44(6):2200062. PMID: 35445427.
• Wong DR, Conrad J*, Johnson NR*, Ayers J, Laeremans A, Lee JC, Lee J, Prusiner SB, Bandyopadhyay S, Butte AJ, Paras NA, Keiser MJ. Trans-channel fluorescence learning improves high-content screening for Alzheimer’s disease therapeutics. Nat Mach Intell. 2022, 4:583–595.
• Lucero EM, Freund RK, Johnson NR, Dooling B, Sullivan E, Prikhodko O, Ahmed MM, Dell'Acqua ML, Chial HJ, Potter H. Kif11 overexpression rescues cognition, long-term potentiation, and spine defects in mouse and cell models of Alzheimer's disease. iScience. 2022, 25(11):105288. PMID: 36304124, PMCID: PMC9593841.
• Rocker AJ, Cavasin M, Johnson NR, Shandas R, Park D. A Sulfonated Thermoresponsive Injectable Gel for Sequential Release of Therapeutic Proteins to Protect Cardiac Function After a Myocardial Infarction. ACS Biomater Sci Eng. 2022, 8(9):3883–3898. PMID: 35950643.